Skip to main
ALEC
ALEC logo

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Alector Inc is advancing its clinical-stage pipeline, showing promising results in neurodegeneration therapies, particularly with AL001, which demonstrated a substantial 48% reduction in clinical progression over 12 months compared to controls. The extended double-blinded treatment period of 96 weeks in the Phase 3 trial is expected to yield even greater improvements in the CDR plus NACC FTLD-SB scores, indicating the potential for enhanced therapeutic efficacy. Furthermore, Alector's innovative approach that targets a novel domain on the transferrin receptor may provide significant advantages in both central nervous system penetration and systemic uptake, reinforcing the positive outlook for the company's future performance.

Bears say

Alector Inc. is experiencing significant challenges inherent to the biopharmaceutical industry, including the risk of unexpected outcomes from clinical trials and regulatory uncertainty. Additionally, the company faces increased pressure from complex and price-sensitive market conditions, which may impact its ability to successfully commercialize its product candidates. Furthermore, specific risks such as potential negative readouts or delays in clinical trials and off-target toxicity in its therapies contribute to a negative outlook on its stock.

Alector Inc (ALEC) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 5 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.